NOVO.B.DK

373

+0.54%↑

COLO.B.DK

566.4

-0.67%↓

GMAB.DK

2,081

+2.41%↑

HLUNB.DK

45.22

-0.13%↓

AMBUB.DK

106.3

+2.11%↑

NOVO.B.DK

373

+0.54%↑

COLO.B.DK

566.4

-0.67%↓

GMAB.DK

2,081

+2.41%↑

HLUNB.DK

45.22

-0.13%↓

AMBUB.DK

106.3

+2.11%↑

NOVO.B.DK

373

+0.54%↑

COLO.B.DK

566.4

-0.67%↓

GMAB.DK

2,081

+2.41%↑

HLUNB.DK

45.22

-0.13%↓

AMBUB.DK

106.3

+2.11%↑

NOVO.B.DK

373

+0.54%↑

COLO.B.DK

566.4

-0.67%↓

GMAB.DK

2,081

+2.41%↑

HLUNB.DK

45.22

-0.13%↓

AMBUB.DK

106.3

+2.11%↑

NOVO.B.DK

373

+0.54%↑

COLO.B.DK

566.4

-0.67%↓

GMAB.DK

2,081

+2.41%↑

HLUNB.DK

45.22

-0.13%↓

AMBUB.DK

106.3

+2.11%↑

Kodu・Aktsiate loetelu・Zealand Pharma A-S

Zealand Pharma A-S

Avatud

503.4 -0.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

502.4

Max

517.8

Põhinäitajad
By Trading Economics
Sissetulek	7.9B 7.6B
Müük	9.1B 9.1B
P/E Sektori keskmine	4.918 35.739
Aktsiakasum	105.61
Kasumimarginaal	83.335
Töötajad	424

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+25.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. nov 2025

Turustatistika
By TradingEconomics
Turukapital	8.7B 32B
Eelmine avamishind	504.34
Eelmine sulgemishind	503.4

Zealand Pharma A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. okt 2025, 08:54 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

12. märts 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20. dets 2024, 09:22 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12. märts 2025, 16:34 UTC

Peamised uudised

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12. märts 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zealand Pharma A-S Prognoos

Hinnasiht

By TipRanks

25.15% tõus

12 kuu keskmine prognoos

Keskmine 270.582 DKK 25.15%

Kõrge 270.568 DKK

Madal 270.568 DKK

Põhineb 1 Wall Streeti analüütiku instrumendi Zealand Pharma A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Zealand Pharma A-S aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.